Literature DB >> 8128041

Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain.

T Ogawa1, I Kanno, J Hatazawa, A Inugami, H Fujita, E Shimosegawa, M Murakami, T Okudera, K Uemura, N Yasui.   

Abstract

Positron emission tomography (PET) with carbon-11 methionine, computed tomography (CT), and magnetic resonance (MR) imaging were performed in 10 patients with histologically verified central nervous system (CNS) lymphoma before and after radiation therapy to compare the radiologic findings and to evaluate the usefulness of PET in monitoring tumor response to radiation therapy. Methionine PET clearly depicted CNS lymphoma before radiation therapy as an increased accumulation of C-11 methionine. The extent of increased accumulation of the radiotracer in tumor tissue markedly decreased after radiation therapy. The area of increased uptake was larger than the enhancing lesions on CT or MR images in most cases. One patient was confirmed to have tumor recurrence at the region of residual increased accumulation on methionine PET images. Methionine PET is useful for the delineation of CNS lymphoma and for monitoring the therapeutic effect of irradiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8128041     DOI: 10.1148/radiographics.14.1.8128041

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  19 in total

1.  Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.

Authors:  Yoshiro Kawase; Yuka Yamamoto; Reiko Kameyama; Nobuyuki Kawai; Nobuyuki Kudomi; Yoshihiro Nishiyama
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

2.  Radiation necrosis of the pons after radiotherapy for nasopharyngeal carcinoma: diagnosis and treatment.

Authors:  Matthew N DeSalvo
Journal:  J Radiol Case Rep       Date:  2012-07-01

3.  Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.

Authors:  Yoshihiro Nishiyama; Yuka Yamamoto; Toshihide Monden; Yasuhiro Sasakawa; Nobuyuki Kawai; Katashi Satoh; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 9.236

Review 4.  Central nervous system lymphoma: characteristic findings on traditional and advanced imaging.

Authors:  I S Haldorsen; A Espeland; E-M Larsson
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

Review 5.  Positron emission tomography in patients with primary CNS lymphomas.

Authors:  U Roelcke; K L Leenders
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

6.  Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine.

Authors:  T Ogawa; S Miura; M Murakami; H Iida; J Hatazawa; A Inugami; I Kanno; N Yasui; T Sasajima; K Uemura
Journal:  Eur J Nucl Med       Date:  1996-08

7.  Contribution of arterial spin-labelling MRI in a case with immune reconstitution inflammatory syndrome.

Authors:  Noriaki Wada; Tomoyuki Noguchi; Takahiro Aoki; Tsuyoshi Tajima
Journal:  BMJ Case Rep       Date:  2017-07-06

8.  MRI perfusion in determining pseudoprogression in patients with glioblastoma.

Authors:  Robert J Young; Ajay Gupta; Akash D Shah; Jerome J Graber; Timothy A Chan; Zhigang Zhang; Weiji Shi; Kathryn Beal; Antonio M Omuro
Journal:  Clin Imaging       Date:  2012-06-08       Impact factor: 1.605

9.  Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas.

Authors:  Yoshinobu Takahashi; Toshiaki Akahane; Daisuke Yamamoto; Hideo Nakamura; Hiroki Sawa; Kazumi Nitta; Wataru Ide; Ikuo Hashimoto; Hajime Kamada
Journal:  Mol Clin Oncol       Date:  2014-05-05

10.  Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.

Authors:  Simone Krebs; Julia G Barasch; Robert J Young; Christian Grommes; Heiko Schöder
Journal:  Ann Lymphoma       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.